405 related articles for article (PubMed ID: 32566583)
1. ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m
Zhang X; Wang F; Wang Z; Yang X; Yu H; Si S; Lu J; Zhou Z; Lu Q; Wang Z; Yang H
Ann Transl Med; 2020 May; 8(10):646. PubMed ID: 32566583
[TBL] [Abstract][Full Text] [Related]
2. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
4. The RNA demethylase ALKBH5 promotes the progression and angiogenesis of lung cancer by regulating the stability of the LncRNA PVT1.
Shen W; Pu J; Zuo Z; Gu S; Sun J; Tan B; Wang L; Cheng J; Zuo Y
Cancer Cell Int; 2022 Nov; 22(1):353. PubMed ID: 36376862
[TBL] [Abstract][Full Text] [Related]
5. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
[TBL] [Abstract][Full Text] [Related]
6. LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m
Fang Y; Wu X; Gu Y; Shi R; Yu T; Pan Y; Zhang J; Jing X; Ma P; Shu Y
Clin Transl Med; 2023 Mar; 13(3):e1205. PubMed ID: 36864711
[TBL] [Abstract][Full Text] [Related]
7. ALKBH5 promotes the progression of infantile hemangioma through regulating the NEAT1/miR-378b/FOSL1 axis.
Peng K; Xia RP; Zhao F; Xiao Y; Ma TD; Li M; Feng Y; Zhou CG
Mol Cell Biochem; 2022 May; 477(5):1527-1540. PubMed ID: 35182329
[TBL] [Abstract][Full Text] [Related]
8. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
[TBL] [Abstract][Full Text] [Related]
9. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
Zhang L; Su X
Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
[TBL] [Abstract][Full Text] [Related]
10. EGR2-mediated regulation of m
Ying Y; Ma X; Fang J; Chen S; Wang W; Li J; Xie H; Wu J; Xie B; Liu B; Wang X; Zheng X; Xie L
Cell Death Dis; 2021 Jul; 12(8):750. PubMed ID: 34326314
[TBL] [Abstract][Full Text] [Related]
11. The m6A demethylase ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of
Li XC; Jin F; Wang BY; Yin XJ; Hong W; Tian FJ
Theranostics; 2019; 9(13):3853-3865. PubMed ID: 31281518
[TBL] [Abstract][Full Text] [Related]
12. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
13. ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis.
Li W; Huang G; Wei J; Cao H; Jiang G
Mol Cell Biochem; 2023 Apr; 478(4):729-741. PubMed ID: 36070054
[TBL] [Abstract][Full Text] [Related]
14. m
Jin D; Guo J; Wu Y; Yang L; Wang X; Du J; Dai J; Chen W; Gong K; Miao S; Li X; Sun H
Mol Cancer; 2020 Feb; 19(1):40. PubMed ID: 32106857
[TBL] [Abstract][Full Text] [Related]
15. Function of AXL and molecular mechanisms in regulation of nasopharyngeal carcinoma.
Zhou K; Zhao J; Xu H; Yan X; Liu W; Jiang X; Ren C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):685-697. PubMed ID: 35837768
[TBL] [Abstract][Full Text] [Related]
16. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
17. ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis.
Yu H; Yang X; Tang J; Si S; Zhou Z; Lu J; Han J; Yuan B; Wu Q; Lu Q; Yang H
Mol Ther Nucleic Acids; 2021 Mar; 23():27-41. PubMed ID: 33376625
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes.
Guimarães-Teixeira C; Barros-Silva D; Lobo J; Soares-Fernandes D; Constâncio V; Leite-Silva P; Silva-Santos R; Braga I; Henrique R; Miranda-Gonçalves V; Jerónimo C
J Pers Med; 2021 Sep; 11(10):. PubMed ID: 34683137
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding protein RNPC1 acts as an oncogene in gastric cancer by stabilizing aurora kinase B mRNA.
Ji CM; Zhang X; Fang W; Meng L; Wei X; Lu C
Exp Cell Res; 2021 Sep; 406(1):112741. PubMed ID: 34302858
[TBL] [Abstract][Full Text] [Related]
20. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification.
Hu Y; Gong C; Li Z; Liu J; Chen Y; Huang Y; Luo Q; Wang S; Hou Y; Yang S; Xiao Y
Mol Cancer; 2022 Feb; 21(1):34. PubMed ID: 35114989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
